NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07053033 2026-03-09
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06528691 2026-02-17
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT07089641 2025-11-24
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06831526 2025-11-12
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT06964737 2025-10-29
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07197632 2025-09-29
MET-MRI
Technical University of Munich
Phase NA Recruiting
NCT06102837 2023-10-26
Tumor Vaccines for Solid Tumors
Huashan Hospital
Recruiting